FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089502717> ?p ?o ?g. }

• W3089502717 endingPage "424" @default.
• W3089502717 startingPage "413" @default.
• W3089502717 abstract "Background: Many Alzheimer’s disease patients in clinical practice are on polypharmacy for treatment of comorbidities. Objective: While pharmacokinetic interactions between drugs have been relatively well established with corresponding treatment guidelines, many medications and common genotype variants also affect central brain circuits involved in cognitive trajectory, leading to complex pharmacodynamic interactions and a large variability in clinical trials. Methods: We applied a mechanism-based and ADAS-Cog calibrated Quantitative Systems Pharmacology biophysical model of neuronal circuits relevant for cognition in Alzheimer’s disease, to standard-of-care cholinergic therapy with COMTVal158Met, 5-HTTLPR rs25531, and APOE genotypes and with benzodiazepines, antidepressants, and antipsychotics, all together 9,585 combinations. Results: The model predicts a variability of up to 14 points on ADAS-Cog at baseline (COMTVV 5-HTTLPRss APOE 4/4 combination is worst) and a four-fold range for the rate of progression. The progression rate is inversely proportional to baseline ADAS-Cog. Antidepressants, benzodiazepines, first-generation more than second generation, and most antipsychotics with the exception of aripiprazole worsen the outcome when added to standard-of-care in mild cases. Low dose second-generation benzodiazepines revert the negative effects of risperidone and olanzapine, but only in mild stages. Non APOE4 carriers with a COMTMM and 5HTTLPRLL are predicted to have the best cognitive performance at baseline but deteriorate somewhat faster over time. However, this effect is significantly modulated by comedications. Conclusion: Once these simulations are validated, the platform can in principle provide optimal treatment guidance in clinical practice at an individual patient level, identify negative pharmacodynamic interactions with novel targets and address protocol amendments in clinical trials." @default.
• W3089502717 created "2020-10-08" @default.
• W3089502717 creator A5084933395 @default.
• W3089502717 creator A5087503813 @default.
• W3089502717 date "2020-10-27" @default.
• W3089502717 modified "2023-09-24" @default.
• W3089502717 title "Simulating the Effects of Common Comedications and Genotypes on Alzheimer’s Cognitive Trajectory Using a Quantitative Systems Pharmacology Approach" @default.
• W3089502717 cites W1610581827 @default.
• W3089502717 cites W1720001930 @default.
• W3089502717 cites W1824736288 @default.
• W3089502717 cites W1935211192 @default.
• W3089502717 cites W1967518376 @default.
• W3089502717 cites W1976700967 @default.
• W3089502717 cites W1977647036 @default.
• W3089502717 cites W1991625887 @default.
• W3089502717 cites W2003804842 @default.
• W3089502717 cites W2012161540 @default.
• W3089502717 cites W2026802237 @default.
• W3089502717 cites W2034475831 @default.
• W3089502717 cites W2040546047 @default.
• W3089502717 cites W2040708659 @default.
• W3089502717 cites W2041128169 @default.
• W3089502717 cites W2048055615 @default.
• W3089502717 cites W2057785387 @default.
• W3089502717 cites W2074398523 @default.
• W3089502717 cites W2074526184 @default.
• W3089502717 cites W2078360327 @default.
• W3089502717 cites W2083090400 @default.
• W3089502717 cites W2085562256 @default.
• W3089502717 cites W2103860290 @default.
• W3089502717 cites W2106095564 @default.
• W3089502717 cites W2132207140 @default.
• W3089502717 cites W2144357260 @default.
• W3089502717 cites W2155997108 @default.
• W3089502717 cites W2157711998 @default.
• W3089502717 cites W2167047846 @default.
• W3089502717 cites W2167862712 @default.
• W3089502717 cites W2168499550 @default.
• W3089502717 cites W2178393107 @default.
• W3089502717 cites W2200279857 @default.
• W3089502717 cites W2217037562 @default.
• W3089502717 cites W2341378930 @default.
• W3089502717 cites W2406840563 @default.
• W3089502717 cites W2514110735 @default.
• W3089502717 cites W2594114440 @default.
• W3089502717 cites W2615616680 @default.
• W3089502717 cites W2772340642 @default.
• W3089502717 cites W2794762477 @default.
• W3089502717 cites W2807299518 @default.
• W3089502717 cites W2883180856 @default.
• W3089502717 cites W2888441878 @default.
• W3089502717 cites W2900856701 @default.
• W3089502717 cites W2910436983 @default.
• W3089502717 cites W2974138729 @default.
• W3089502717 cites W2976575922 @default.
• W3089502717 cites W2977078964 @default.
• W3089502717 cites W2982868520 @default.
• W3089502717 cites W3002204673 @default.
• W3089502717 cites W3015016963 @default.
• W3089502717 doi "https://doi.org/10.3233/jad-200688" @default.
• W3089502717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33016912" @default.
• W3089502717 hasPublicationYear "2020" @default.
• W3089502717 type Work @default.
• W3089502717 sameAs 3089502717 @default.
• W3089502717 citedByCount "4" @default.
• W3089502717 countsByYear W30895027172021 @default.
• W3089502717 countsByYear W30895027172023 @default.
• W3089502717 crossrefType "journal-article" @default.
• W3089502717 hasAuthorship W3089502717A5084933395 @default.
• W3089502717 hasAuthorship W3089502717A5087503813 @default.
• W3089502717 hasConcept C111113717 @default.
• W3089502717 hasConcept C112705442 @default.
• W3089502717 hasConcept C118552586 @default.
• W3089502717 hasConcept C126322002 @default.
• W3089502717 hasConcept C143998085 @default.
• W3089502717 hasConcept C15744967 @default.
• W3089502717 hasConcept C169900460 @default.
• W3089502717 hasConcept C2776412080 @default.
• W3089502717 hasConcept C2776619155 @default.
• W3089502717 hasConcept C2779134260 @default.
• W3089502717 hasConcept C2779483572 @default.
• W3089502717 hasConcept C2780211496 @default.
• W3089502717 hasConcept C2780904820 @default.
• W3089502717 hasConcept C36434225 @default.
• W3089502717 hasConcept C71924100 @default.
• W3089502717 hasConcept C98274493 @default.
• W3089502717 hasConceptScore W3089502717C111113717 @default.
• W3089502717 hasConceptScore W3089502717C112705442 @default.
• W3089502717 hasConceptScore W3089502717C118552586 @default.
• W3089502717 hasConceptScore W3089502717C126322002 @default.
• W3089502717 hasConceptScore W3089502717C143998085 @default.
• W3089502717 hasConceptScore W3089502717C15744967 @default.
• W3089502717 hasConceptScore W3089502717C169900460 @default.
• W3089502717 hasConceptScore W3089502717C2776412080 @default.
• W3089502717 hasConceptScore W3089502717C2776619155 @default.
• W3089502717 hasConceptScore W3089502717C2779134260 @default.
• W3089502717 hasConceptScore W3089502717C2779483572 @default.
• W3089502717 hasConceptScore W3089502717C2780211496 @default.

• next